EQS-Adhoc

RHÖN-KLINIKUM Aktiengesellschaft: EBITDA for 2022 above the forecast range on the basis of preliminary figures

EQS-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Preliminary Results RHÖN-KLINIKUM Aktiengesellschaft: EBITDA for 2022 above the forecast range on the basis of preliminary figures 30-Jan-2023 / 14:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. In the course of preparing the consolidated financial statements for the past financial year, the Management Board of RHÖN-KLINIKUM Aktiengesellschaft now assumes that the Group's earnings before interest, taxes, depreciation and amortisation (EBITDA) will be above the forecast published by the company in March 2022 (EBITDA value between EUR 92 million and EUR 102 million). Based on preliminary and unaudited figures, the Management Board currently estimates that the Group's EBITDA will be in a range between EUR 103 million and EUR 109 million. The Annual Report 2022 and further information on the past financial year will be published on 30 March 2023. Contact: Julian Schmitt Head of Investor Relations & Treasury [phone] 30-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

---

Language:	English
Company:	RHÖN-KLINIKUM Aktiengesellschaft
	Salzburger Leite 1
	97616 Bad Neustadt a.d.Saale
	Germany
Phone:	+49 (0)9771 - 65-0
Fax:	+49 (0)9771 - 97 467
E-mail:	[e-mail]
Internet:	www.rhoen-klinikum-ag.com
ISIN:	DE0007042301
WKN:	704230
Listed:	Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID:	1546697

End of Announcement	EQS News Service

1546697  30-Jan-2023 CET/CEST